selected scholarly activity
-
academic article
- Pilot study of an elimination diet in adults with mild to moderate Crohn’s disease. European Journal of Gastroenterology and Hepatology. 34:1210-1219. 2022
- Long-Term Outcomes of Early vs Delayed Responders to Vedolizumab and Adalimumab: A Post Hoc Analysis of the VARSITY Study. American Journal of Gastroenterology. Publish Ahead of Print. 2022
- Effectiveness of Tofacitinib for Hospitalized Patients with Acute Severe Ulcerative Colitis: Case Series. Digestive Diseases and Sciences. 67:5213-5219. 2022
- Most Placebo-Controlled Trials in Inflammatory Bowel Disease were Underpowered Because of Overestimated Drug Efficacy Rates: Results from a Systematic Review of Induction Studies. Journal of Crohn's and Colitis. jjac150. 2022
- Decision Support Tool Identifies Ulcerative Colitis Patients Most Likely to Achieve Remission With Vedolizumab vs Adalimumab. Inflammatory Bowel Diseases. 28:1555-1564. 2022
- Case Report: Managing Postoperative Crohn’s Disease. Gastroenterology and Hepatology. 18:568-573. 2022
- Week 2 Adalimumab Levels Predict Short-term Clinical Remission in Patients With Inflammatory Bowel Disease. Journal of Clinical Gastroenterology. 56:794-797. 2022
- Ulcer Size After Induction Therapy Performs Better Than Symptom Assessment for Prediction of One Year Endoscopic Remission in Crohn’s Disease: A Post Hoc Analysis. Inflammatory Bowel Diseases. izac210. 2022
- Beyond the White Pill: Advocating for Racial Diversity in IBD Trials. Journal of Crohn's and Colitis. jjac134. 2022
- Time to Endorse A Sensitive Method for Scoring Endoscopic Activity of Ulcerative Colitis in Clinical Research. Journal of Crohn's and Colitis. jjac120. 2022
- Categorising Endoscopic Severity of Crohn’s Disease Using the Modified Multiplier SES-CD [MM-SES-CD]. Journal of Crohn's and Colitis. 16:1011-1019. 2022
- Comparative Efficacy of Infliximab vs Ustekinumab for Maintenance of Clinical Response in Biologic Naïve Crohn’s Disease. Inflammatory Bowel Diseases. izac168. 2022
- Predictors of Placebo Induction Response and Remission in Ulcerative Colitis. Clinical Gastroenterology and Hepatology. S1542-3565(22)00811-4. 2022
- End of induction patient reported outcomes predict clinical remission and endoscopic improvement with vedolizumab and adalimumab in ulcerative colitis. Scandinavian Journal of Gastroenterology. 1-8. 2022
- Increased Expression of Interleukin-13 Receptor in Ileum Associated With Nonresponse to Adalimumab in Ileal Crohn’s Disease. Inflammatory Bowel Diseases. izac157. 2022
- Comparative Efficacy and Rapidity of Action for Infliximab vs Ustekinumab in Biologic Naïve Crohn’s Disease. Clinical Gastroenterology and Hepatology. 20:1579-1587.e2. 2022
- Comparative Efficacy for Infliximab Vs Vedolizumab in Biologic Naive Ulcerative Colitis. Clinical Gastroenterology and Hepatology. 20:1588-1597.e3. 2022
- Comparison of the Relative Sensitivity of Clinical, Endoscopic, and Histologic Remission for Detection of Treatment Efficacy in Ulcerative Colitis Trials. Inflammatory Bowel Diseases. izac128. 2022
- Correspondence on “PICaSSO Histologic Remission Index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and predicting clinical outcomes and its applicability in an artificial intelligence system” by Guiet al. Gut. gutjnl-2022-327661. 2022
- Predicting endoscopic remission in Crohn’s disease by the modified multiplier SES-CD (MM-SES-CD). Gut. 71:1078-1087. 2022
- Reply. Clinical Gastroenterology and Hepatology. 20:e1510-e1511. 2022
- Ustekinumab does not increase risk of new or recurrent cancer in inflammatory bowel disease patients with prior malignancy. Journal of Gastroenterology and Hepatology (Australia). 37:1016-1021. 2022
- Early Reduction in MM-SES-CD Score After Initiation of Biologic Therapy is Highly Specific for 1-year Endoscopic Remission in Moderate to Severe Crohn’s Disease. Journal of Crohn's and Colitis. 16:616-624. 2022
- Clinical Decision Support Tool for Infliximab in Crohn’s Disease. Clinical Gastroenterology and Hepatology. 20:e1192-e1195. 2022
- Early Change in Epithelial Neutrophilic Infiltrate Predicts Long-Term Response to Biologics in Ulcerative Colitis. Clinical Gastroenterology and Hepatology. 20:1095-1104.e9. 2022
- Periodic Colonoscopies Are Associated with Improved Survival and Prognosis of Colorectal Cancer in Ulcerative Colitis. Digestive Diseases and Sciences. 67:1850-1857. 2022
- Reply. Clinical Gastroenterology and Hepatology. 20:e1216-e1217. 2022
- Resolution of dominant patient‐reported outcome at end of induction predicts clinical and endoscopic remission in Crohn’s disease. Alimentary Pharmacology and Therapeutics. 55:1151-1159. 2022
- Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis. Scandinavian Journal of Gastroenterology. 57:424-431. 2022
-
Editorial: is it not just
PRO s, but the most important individualPRO , that really matters in Crohn’s disease? Authors’ reply. Alimentary Pharmacology and Therapeutics. 55:1040-1041. 2022 - Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis. BMJ Open Gastroenterology. 9:e000853-e000853. 2022
- Host Genetic Determinants Associated With Helicobacter pylori Eradication Treatment Failure: A Systematic Review and Meta-analysis. Gastroenterology. 161:1443-1459. 2021
- Outcomes of Passable and Non-passable Strictures in Clinical Trials of Crohn’s Disease: A Post-hoc Analysis. Journal of Crohn's and Colitis. 15:1649-1657. 2021
- Declining Use of Corticosteroids for Crohn’s Disease Has Implications for Study Recruitment: Results of a Pilot Randomized Controlled Trial. Journal of the Canadian Association of Gastroenterology. 4:214-221. 2021
- Comparative effectiveness of higher adalimumab maintenance therapy versus standard dose in anti‐tumor necrosis factor experienced Crohn's disease patients: A propensity‐score matched cohort analysis. Journal of Gastroenterology and Hepatology (Australia). 36:2803-2812. 2021
- Does a High-inflammatory Diet Increase the Risk of Inflammatory Bowel Disease? Results From the Prospective Urban Rural Epidemiology (PURE) Study: A Prospective Cohort Study. Gastroenterology. 161:1333-1335.e1. 2021
- Higher adalimumab maintenance regimen is more effective than standard dose in anti-TNF experienced Crohn’s disease patients. European Journal of Gastroenterology and Hepatology. 33:1274-1279. 2021
- Systematic review and meta‐analysis: Safety of vedolizumab during pregnancy in patients with inflammatory bowel disease. Journal of Gastroenterology and Hepatology (Australia). 36:2640-2648. 2021
- Prevalence and Progression of Incidental Terminal Ileitis on Non-diagnostic Colonoscopy: A Systematic Review and Meta-analysis. Journal of Crohn's and Colitis. 15:1455-1463. 2021
- Intake of artificial sweeteners among adults is associated with reduced odds of gastrointestinal luminal cancers: a meta-analysis of cohort and case-control studies. Nutrition Research. 93:87-98. 2021
- Medical Management Following Surgical Therapy in Inflammatory Bowel Disease: Evidence from Cochrane Reviews. Inflammatory Bowel Diseases. 27:1513-1524. 2021
- A Microsimulation Model to Determine the Cost-Effectiveness of Treat-to-Target Strategies for Crohn's Disease. American Journal of Gastroenterology. 116:1709-1719. 2021
- Association of ultra-processed food intake with risk of inflammatory bowel disease: prospective cohort study. British Medical Journal BMJ (Clinical research ed.). 374:n1554-n1554. 2021
- End of Induction Patient-reported Outcomes Predict Clinical Remission but Not Endoscopic Remission in Crohn’s Disease. Journal of Crohn's and Colitis. 15:1114-1119. 2021
- Early life exposures and the risk of inflammatory bowel disease: Systematic review and meta-analyses. EClinicalMedicine. 36:100884-100884. 2021
- The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: A post hoc analysis of the UNITI studies. United European Gastroenterology Journal. 9:581-589. 2021
- Body Mass Index Does Not Impact Clinical Efficacy of Ustekinumab in Crohn’s Disease: A Post Hoc Analysis of the IM-UNITI Trial. Inflammatory Bowel Diseases. 27:848-854. 2021
- Editorial: methotrexate in patients with Crohn's disease refractory to anti-TNF therapy-moving backwards yet forward?. Alimentary Pharmacology and Therapeutics. 53:950-951. 2021
- Week 6 Calprotectin Best Predicts Likelihood of Long-term Endoscopic Healing in Crohn’s Disease: A Post-hoc Analysis of the UNITI/IM-UNITI Trials. Journal of Crohn's and Colitis. 15:462-470. 2021
- Active Margins, Plexitis, and Granulomas Increase Postoperative Crohn’s Recurrence: Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology. 19:451-462. 2021
- Effect of Concomitant Therapy With Steroids and Tumor Necrosis Factor Antagonists for Induction of Remission in Patients With Crohn’s Disease: A Systematic Review and Pooled Meta-analysis. Clinical Gastroenterology and Hepatology. 19:238-245.e4. 2021
- Impact of Digital Health Monitoring in the Management of Inflammatory Bowel Disease. Journal of Medical Systems. 45:23. 2021
- Mode of Delivery Does Not Affect the Risk of Inflammatory Bowel Disease. Digestive Diseases and Sciences. 66:398-407. 2021
- Risk of Postoperative Infectious Complications From Medical Therapies in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Inflammatory Bowel Diseases. 26:1796-1807. 2020
- Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease. Cohrane Library Clinical Respiratory Journal. 2021:CD013256. 2020
- Ileal and Rectal Ulcer Size Affects the Ability to Achieve Endoscopic Remission: A Post hoc Analysis of the SONIC Trial. American Journal of Gastroenterology. 115:1236-1245. 2020
- Higher vedolizumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel disease. Scandinavian Journal of Gastroenterology. 55:800-805. 2020
- Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors. American Journal of Gastroenterology. 115:885-894. 2020
- Letter: mesalazine-a safe drug with rare serious adverse events? Authors’ reply. Alimentary Pharmacology and Therapeutics. 51:1212-1212. 2020
- Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitis. Alimentary Pharmacology and Therapeutics. 51:435-445. 2020
- Is Blood Urea Concentration an Independent Predictor of Positive Endoscopic Findings in Presumed Upper Gastrointestinal Bleeding?. Digestive Diseases. 38:77-84. 2020
- Risk for development of inflammatory bowel disease under inhibition of interleukin 17: A systematic review and meta-analysis. PLoS ONE. 15:e0233781-e0233781. 2020
- Association Between Helicobacter pylori Exposure and Decreased Odds of Eosinophilic Esophagitis—A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology. 17:2185-2198.e3. 2019
- Response to Letter by Moulton et al.. Inflammatory Bowel Diseases. 25:e99-e99. 2019
- Systematic review with meta-analysis: association betweenHelicobacter pyloriCagA seropositivity and odds of inflammatory bowel disease. Alimentary Pharmacology and Therapeutics. 50:121-131. 2019
- Anxiety But Not Depression Predicts Poor Outcomes in Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 25:1255-1261. 2019
- Higher adalimumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel disease. Scandinavian Journal of Gastroenterology. 54:712-717. 2019
- Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease. Cohrane Library Clinical Respiratory Journal. 2019. 2019
- Patient-Reported Outcomes and Endoscopic Appearance of Ulcerative Colitis: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology. 17:411-418.e3. 2019
- Impact of Adalimumab Patient Support Program’s Care Coach Calls on Clinical Outcomes in Patients with Crohn’s Disease in Canada: An Observational Retrospective Cohort Study. Journal of the Canadian Association of Gastroenterology. 1:191-198. 2018
- Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. American Journal of Gastroenterology. 113:1912-1912. 2018
- Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn’s Disease. Gastroenterology. 155:687-695.e10. 2018
- Open: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. American Journal of Gastroenterology. 113:1345-1345. 2018
- Safety of Propofol versus Nonpropofol-Based Sedation in Children Undergoing Gastrointestinal Endoscopy: A Systematic Review and Meta-Analysis. Gastroenterology Research and Practice. 2018:1-11. 2018
- The Role of Biomarkers in Clinical Trials of Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 24:1619-1623. 2018
- Systematic review: safety of mesalazine in ulcerative colitis. Alimentary Pharmacology and Therapeutics. 47:1597-1609. 2018
- Role of endoscopy in inflammatory bowel disease. Gastroenterology Report. 6:75-82. 2018
- Systematic Review and Meta-Analysis: Preoperative Vedolizumab Treatment and Postoperative Complications in Patients with Inflammatory Bowel Disease. Journal of Crohn's and Colitis. 12:538-545. 2018
- Enteral nutritional therapy for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews. 2018:CD000542. 2018
- Systematic Review and Meta-analysis. Inflammatory Bowel Diseases. 23:1702-1709. 2017
- Systematic Review and Meta-analysis: Fecal Microbiota Transplantation for Treatment of Active Ulcerative Colitis.. Inflammatory Bowel Diseases. 23:1702-1709. 2017
- Systematic review with meta-analysis: proximal disease extension in limited ulcerative colitis. Alimentary Pharmacology and Therapeutics. 45:1481-1492. 2017
- Trends in Narcotic and Corticosteroid Prescriptions in Patients with Inflammatory Bowel Disease in the United States Ambulatory Care Setting from 2003 to 2011. Inflammatory Bowel Diseases. 23:868-874. 2017
- The morbidity and mortality of hepaticojejunostomies for complex bile duct injuries: a multi-institutional analysis of risk factors and outcomes using NSQIP. HPB. 19:352-358. 2017
- Review article: dose optimisation of infliximab for acute severe ulcerative colitis. Alimentary Pharmacology and Therapeutics. 45:617-630. 2017
- Preventive care for a 35-year-old woman with inflammatory bowel disease. CMAJ. 189:E243-E244. 2017
- Impact of High-Dose Vitamin D3 Supplementation in Patients with Crohn’s Disease in Remission: A Pilot Randomized Double-Blind Controlled Study. Digestive Diseases and Sciences. 62:448-455. 2017
- Management Strategies to Improve Outcomes of Patients With Inflammatory Bowel Diseases. Gastroenterology. 152:351-361.e5. 2017
- Letter: comparative safety and efficacy of infliximab vs. adalimumab in Crohn's disease - should one consider disease location? Authors’ reply. Alimentary Pharmacology and Therapeutics. 44:772-773. 2016
- Mucosal Healing Is Associated With Improved Long-term Outcomes of Patients With Ulcerative Colitis: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology. 14:1245-1255.e8. 2016
- Reply. Clinical Gastroenterology and Hepatology. 14:1361-1362. 2016
- The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium. American Journal of Gastroenterology. 111:1147-1155. 2016
- The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-TNF-α naïve Crohn's disease. Alimentary Pharmacology and Therapeutics. 44:170-180. 2016
- Letter: mucosal healing is associated with improved long-term outcomes in Crohn's disease - authors' reply. Alimentary Pharmacology and Therapeutics. 43:1347-1348. 2016
- Adverse Events During Anti-TNFα Therapies in IBD (Excluding Infections and Malignancies). Inflammatory Bowel Diseases. 22:1239-1245. 2016
- Systematic Review and Meta-Analysis: Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory to Steroids. American Journal of Gastroenterology. 111:477-491. 2016
- Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn's disease. Alimentary Pharmacology and Therapeutics. 43:317-333. 2016
- When to perform gastroscopy in the PSC patient. Annals of Hepatology. 15:135-136. 2016
- Systematic Review. Inflammatory Bowel Diseases. 21:1683-1694. 2015
- Management of Severe Ulcerative Colitis. Current Treatment Options in Gastroenterology. 13:59-76. 2015
- Anti-TNFα Therapies Are Safe During Pregnancy in Women with Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 20:1862-1869. 2014
- Combination Therapy With Methotrexate in Inflammatory Bowel Disease: Time to COMMIT?. Gastroenterology. 146:608-611. 2014
- Fecal Occult Blood Testing as a Diagnostic Test in Symptomatic Patients is not Useful: A Retrospective Chart Review. Canadian Journal of Gastroenterology and Hepatology. 28:421-426. 2014
- Does acetylsalicylic acid or warfarin affect the accuracy of fecal occult blood tests?. Journal of Gastroenterology and Hepatology (Australia). 28:931-936. 2013
- Meta-analysis: peri-operative anti-TNFα treatment and post-operative complications in patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics. 37:1057-1064. 2013
- Meta-analysis: colonoscopic post-polypectomy bleeding in patients on continued clopidogrel therapy. Alimentary Pharmacology and Therapeutics. 37:947-952. 2013
- An evaluation of the ‘5 Minute Medicine’ video podcast series compared to conventional medical resources for the internal medicine clerkship. Medical Teacher. 34:e751-e755. 2012
- Are Patients with Inflammatory Bowel Disease at Increased Risk of Coronary Artery Disease?. American Journal of Medicine. 125:956-962. 2012
- Management of inflammatory bowel disease with vitamin D: Beyond bone health. Journal of Crohn's and Colitis. 6:397-404. 2012
- An Audit of Influenza Vaccination Status in Adults with Inflammatory Bowel Disease. Canadian Journal of Gastroenterology. 26:593-596. 2012
- Should Albumin Be Used in All Patients with Spontaneous Bacterial Peritonitis?. Canadian Journal of Gastroenterology. 25:373-376. 2011
- Role of probiotics in management of diverticular disease. Journal of Gastroenterology and Hepatology (Australia). 25:1827-1830. 2010
- IgG4-Related Sclerosing Disease: A Novel Mimic of Inflammatory Bowel Disease. Digestive Diseases and Sciences. 55:3047-3051. 2010
- Should My Patient with Inflammatory Bowel Disease on Immunosuppressive Therapy be Vaccinated against Influenza Virus?. Canadian Journal of Gastroenterology. 24:121-125. 2010
- Does Smoking Reduce Infliximab’s Effectiveness against Crohn’s Disease?. Canadian Journal of Gastroenterology. 23:121-125. 2009
- Exercise and Inflammatory Bowel Disease. Canadian Journal of Gastroenterology. 22:497-504. 2008
-
conference paper
- Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn's Disease. American Journal of Gastroenterology. 1106-1117. 2022
- The Performance of the Rutgeerts Score, SES-CD, and MM-SES-CD for Prediction of Postoperative Clinical Recurrence in Crohn’s Disease. Inflammatory Bowel Diseases. izac130. 2022
- Histologic remission does not offer additional benefit for ulcerative colitis patients in endoscopic remission.. Alimentary Pharmacology and Therapeutics. 1676-1682. 2020
- WEEK 2 ADALIMUMAB LEVEL PREDICTS SHORT-TERM CLINICAL REMISSION IN PATIENTS WITH IBD. Gastroenterology. S1142-S1142. 2019
- Mode of delivery and risk of inflammatory bowel disease. Journal of Crohn's and Colitis. S514-S515. 2019
- Surveillance colonoscopies in ulcerative colitis: does it make a difference?. Journal of Crohn's and Colitis. S70-S70. 2019
- P607 Higher adalimumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel disease. Journal of Crohn's and Colitis. S420-S420. 2019
- Higher adalimumab maintenance regimens are more effective than standard maintenance doses in Crohn's disease patients who have failed infliximab. Journal of Crohn's and Colitis. S325-S326. 2018
- Pre-operative vedolizumab treatment and postoperative complications in patients with inflammatory bowel disease: A systematic review and meta-analysis. Journal of Crohn's and Colitis. S333-S334. 2018
- Systematic review and meta-analysis: Patient-reported outcomes and endoscopic appearance in ulcerative colitis. Journal of Crohn's and Colitis. S195-S195. 2018
- Higher Adalimumab Maintenance Regimens Are More Effective Than Standard Maintenance Regimens in Crohnʼs Disease Patients Who Have Failed Infliximab. American Journal of Gastroenterology. S412-S413. 2017
- Systematic review with meta-analysis: enteral nutrition therapy for the induction of remission in paediatric Crohn's disease. Alimentary Pharmacology and Therapeutics. 645-656. 2017
- Persistent Symptoms, CRP Elevation and Treatment Changes Over Time in Crohn's Disease Patients are Associated with Bowel Damage Progression as Expressed by Deterioration of Lemann Index Score. Gastroenterology. S784-S784. 2017
- Proximal Disease Extension in Limited Ulcerative Colitis: A Systematic Review and Meta-Analysis. Gastroenterology. S976-S976. 2017
- Ulcerative Colitis Patients on Vedolizumab Lacking Response at Induction Phase Continue to Improve Over the First 6 Months of Treatment. Gastroenterology. S400-S401. 2017
- C-reactive protein improvement after vedolizumab induction phase is associated with remission after 6 months of treatment in ulcerative colitis patients. Journal of Crohn's and Colitis. S190-S190. 2017
- Impact of adalimumab's patient support program on clinical outcomes in inflammatory bowel diseases: results from the COMPANION study. Journal of Crohn's and Colitis. S438-S439. 2017
- Persistent symptoms, CRP elevation and treatment changes over time in Crohn's disease patients are associated with bowel damage progression as expressed by deterioration of Lemann Index score. Journal of Crohn's and Colitis. S227-S228. 2017
- Proximal Disease Extension in Limited Ulcerative Colitis: A Systematic Review and Meta-Analysis. Inflammatory Bowel Diseases. S21-S21. 2017
- Proximal disease extension in limited ulcerative colitis: a systematic review and meta-analysis. Journal of Crohn's and Colitis. S28-S28. 2017
- Trends in narcotic and corticosteroid prescriptions in patients with inflammatory bowel disease in the United States ambulatory care setting from 2003 to 2011. Journal of Crohn's and Colitis. S288-S288. 2017
- Ulcerative colitis patients on vedolizumab lacking response at induction phase continue to improve over the first 6 months of treatment. Journal of Crohn's and Colitis. S334-S335. 2017
- PUB006 Impact of the New WHO Classification of Thymic Tumors: Cross-Validation of the Prognostic Value in a Single Institution Cohort. Journal of Thoracic Oncology. S1448-S1449. 2017
- Prognostic Value of the New WHO Thymoma Classification: Single institution Cross Validation Study. Journal of Thoracic Oncology. S284-S285. 2016
- Outcomes of Second- and Third-LineTumor Necrosis Factor-α Antagonists in Inflammatory Bowel Disease. American Journal of Gastroenterology. S428-S429. 2016
- Rho Kinase Ezpression in Giant Cell Arteritis: Validating Perm Intensity Score As a Method of Increasing Sensitivity of Temporal Artery Biopsy. Arthritis and Rheumatology. 2016
- Sa1888 Efficacy and Predictors of Outcomes of Vedolizumab for Ulcerative Colitis in Clinical Practice. Gastroenterology. S392-S393. 2016
- Sa1889 Efficacy and Predictors of Outcomes of Vedolizumab for Crohn's Disease in Clinical Practice. Gastroenterology. S393-S393. 2016
- Tu1908 Safety of Vedolizumab in Inflammatory Bowel Disease in a Multi-Center Real World Consortium. Gastroenterology. S974-S974. 2016
- Impact of high-dose vitamin D3 supplementation in treatment of Crohn's disease in remission: a randomised double-blind controlled study. Journal of Crohn's and Colitis. S429-S430. 2016
- Mucosal Healing Is Associated with Improved Long-Term Outcomes in Crohn's Disease: A Systematic Review and Meta-analysis. Inflammatory Bowel Diseases. S14-S14. 2016
- Mucosal Healing Is Associated with Improved Long-Term Outcomes in Ulcerative Colitis: A Systematic Review and Meta-analysis. Inflammatory Bowel Diseases. S14-S14. 2016
- P-064 Impact of High Dose Vitamin D3 Supplementation in Treatment of Crohnʼs Disease in Remission. Inflammatory Bowel Diseases. S29-S30. 2016
- Mucosal Healing Is Associated With Improved Long-Term Outcomes in Ulcerative Colitis: A Systematic Review and Meta-analysis Presidential Poster. American Journal of Gastroenterology. S827-S827. 2015
- Vedolizumab for Moderate to Severely Active Inflammatory Bowel Disease: A Multicenter U.S. Consortium. American Journal of Gastroenterology. S809-S809. 2015
- Systematic Review and Meta-Analysis: Infliximab or Ciclosporin as Rescue Therapy in Patients with Severe Ulcerative Colitis Refractory to Steroids. Journal of Crohn's and Colitis. S313-S313. 2015
- Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory to Steroids: A Systematic Review and Meta-Analysis. American Journal of Gastroenterology. S524-S524. 2014
- Anti-TNF alpha Therapies Are Safe During Pregnancy in Women With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Gastroenterology. S582-S583. 2014
- DOP040 Anti-TNF-α therapies are safe during pregnancy in patients with inflammatory bowel disease: a meta-analysis. Journal of Crohn's and Colitis. S34-S34. 2014
- An Audit of Fecal Occult Blood Testing in Hospital Inpatients. American Journal of Gastroenterology. S495-S495. 2013
- Peri-operative Anti-TNFα Treatment and Post-operative Complications in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. American Journal of Gastroenterology. S551-S551. 2013